Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Liver Disease Clear all
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

NCT01464827
View directory record Official record
Conditions
Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions
ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
60
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 3 Interventional Results available

PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C

NCT00100659
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pegylated Interferon/ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jul 23, 2026, 1:52 PM EDT
Terminated Phase 4 Interventional Results available

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

NCT04515797
View directory record Official record
Conditions
Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions
Glecaprevir and Pibrentasvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jul 23, 2026, 1:52 PM EDT
Terminated Phase 4 Interventional

Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin

NCT00194857
View directory record Official record
Conditions
Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
Interventions
erythropoietin, GCSF
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jul 23, 2026, 1:52 PM EDT
Recruiting Not applicable Interventional

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

NCT05486572
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Cirrhosis
Interventions
Abbreviated Magnetic Resonance Imaging with serum AFP, Abdominal Ultrasound Screening with serum AFP
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
4,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 1:52 PM EDT
No Longer Available No phase listed Expanded access

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

NCT02161939
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir (BMS-790052), Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

NCT03036839
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Not applicable Interventional Results available

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

NCT01747772
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
Interventions
Shear Wave Sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

NCT02094443
View directory record Official record
Conditions
Hepatitis C, Liver Disease
Interventions
Alisporivir, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Bakersfield, California • Lancaster, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 1 Interventional

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

NCT00971308
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-824393
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Anaheim, California • Cypress, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jul 23, 2026, 1:52 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

NCT01037621
View directory record Official record
Conditions
Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
Interventions
Valacyclovir
Drug
Lead sponsor
G.V. (Sonny) Montgomery VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

NCT01909804
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 1 Interventional

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

NCT00343525
View directory record Official record
Conditions
Hepatitis C
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Sarasota, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis

NCT00973817
View directory record Official record
Conditions
Acute On Chronic Hepatitis
Interventions
ELAD plus standard of care treatment, Standard of care
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 3 Interventional

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

NCT05630807
View directory record Official record
Conditions
Chronic Hepatitis B, Hepatitis B, Chronic
Interventions
Bepirovirsen, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Chandler, Arizona • Davis, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 1:52 PM EDT
Terminated No phase listed Observational

AIH Risk Stratification With Multiparametric MRI

NCT04339621
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
LiverMultiscan
Device
Lead sponsor
Perspectum
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 23, 2026, 1:52 PM EDT
Completed No phase listed Observational

Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.

NCT00263614
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

NCT06974565
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Quinidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
La Jolla, California • Long Beach, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jul 23, 2026, 1:52 PM EDT
Completed Phase 1Phase 2 Interventional

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

NCT00559247
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032 or Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Cypress, California • Orlando, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Jul 23, 2026, 1:52 PM EDT